Research Analysts’ Weekly Ratings Updates for Immune Design (IMDZ)

Share on StockTwits

Several analysts have recently updated their ratings and price targets for Immune Design (NASDAQ: IMDZ):

  • 10/16/2018 – Immune Design was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $2.00 price target on the stock. According to Zacks, “Immune Design's primary candidate, G100 is being developed for merkel cell carcinoma, follicular non-Hodgkin Lymphoma and sarcoma. We are positive about its strategic agreements with companies like Sanofi, Roche and Merck, which not only validate its GLAAS platform but also provide the company with funds in the form of collaboration and license revenues. Although such collaborations boost its pipeline development, heavy dependence on other companies for revenue growth increases the company’s vulnerability too. However, Immune Design in October 2018, discontinued CMB305 cancer vaccine program following a review of its portfolio. Shares of the company underperformed the industry, year to date. Loss estimates have narrowed ahead opf the Q3 earnings release.”
  • 10/12/2018 – Immune Design had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $11.00 price target on the stock.
  • 10/12/2018 – Immune Design was downgraded by analysts at Leerink Swann from an “outperform” rating to a “market perform” rating.
  • 10/12/2018 – Immune Design was given a new $8.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 10/3/2018 – Immune Design was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Immune Design's primary candidate, CMB305, is being evaluated for soft tissue sarcoma while the other candidate G100 is being developed for merkel cell carcinoma, follicular non-Hodgkin Lymphoma and sarcoma Immune Design recently initiated a pivotal phase III studyevaluating CMB305 as monotherapy on synovial sarcoma patients. The company is working toward the potential registration paths of these products. We are positive about its strategic agreements with companies like Sanofi, Roche and Merck, which not only validate its GLAAS platform but also provide the company with funds in the form of collaboration and license revenues. Although such collaborations boost its pipeline development, heavy dependence on other companies for revenue growth increases the company’s vulnerability too.Shares of the company underperformed the industry, year to date.”

Shares of IMDZ stock traded up $0.15 on Tuesday, reaching $1.50. 61,939 shares of the company were exchanged, compared to its average volume of 741,670. The stock has a market capitalization of $68.88 million, a P/E ratio of -0.86 and a beta of 1.77. Immune Design Corp has a 1 year low of $1.29 and a 1 year high of $5.30.

Immune Design (NASDAQ:IMDZ) last released its earnings results on Wednesday, August 1st. The biotechnology company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.01. The business had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.64 million. Immune Design had a negative net margin of 2,324.21% and a negative return on equity of 46.95%. On average, equities research analysts expect that Immune Design Corp will post -1.2 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in IMDZ. Portolan Capital Management LLC purchased a new stake in shares of Immune Design during the second quarter worth about $2,024,000. Dimensional Fund Advisors LP grew its stake in Immune Design by 132.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 447,026 shares of the biotechnology company’s stock valued at $2,034,000 after acquiring an additional 254,696 shares in the last quarter. BlackRock Inc. grew its stake in Immune Design by 10.6% during the 2nd quarter. BlackRock Inc. now owns 2,121,271 shares of the biotechnology company’s stock valued at $9,651,000 after acquiring an additional 204,171 shares in the last quarter. Alps Advisors Inc. purchased a new stake in Immune Design during the 2nd quarter valued at about $318,000. Finally, Essex Investment Management Co. LLC purchased a new stake in Immune Design during the 2nd quarter valued at about $192,000. 49.33% of the stock is owned by institutional investors and hedge funds.

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.

Read More: Momentum Indicator: Relative Strength Index

Receive News & Ratings for Immune Design Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply